EU Investigating Ozempic After Suicidal Thoughts Reported
Novo Nordisk’s shares fell 1 percent on Monday after news of the probe broke.

GEORGE FREY/Reuters
Get the Beast Digest newsletter delivered straight to your inbox
By clicking “SIGN UP” you agree to our Terms of Use and Privacy Policy.
The European Medicines Agency (EMA)—the EU’s pharmaceutical supervisory branch—is probing the creator of popular diabetes and weight-loss drug Ozempic. Drugmaker Novo Nordisk will have its weight-loss drugs, including Ozempic, Saxenda and Wegovy, investigated after Iceland’s health regulator flagged three cases of patients reporting suicidal thoughts. But the Danish drugmaker said in a statement that it hasn’t seen a “causal association” between the active ingredients in the drugs and “suicidal and self-harming thoughts.” Novo Nordisk rose to prominence after the viral success of Ozempic, which has become so popular as a weight loss solution that there was a shortage last year, impacting many diabetes patients. The company’s shares fell 1 percent on Monday after news of the probe broke, according to Reuters.
Unlock a year of full access to The Daily Beast for $35.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Looks like you already have a subscription!
- Account (completed)
- Payment (completed)
- Confirmation (completed)
You're all set!
Thanks for subscribing.
- 1Account
- 2Payment
- 3Confirmation
Sign in or create an account
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
- Account (completed)
- Payment (completed)
- Confirmation (completed)
You're all set!
Thanks for subscribing.
- 1Account
- 2Payment
- 3Confirmation